Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Schattenberg
L Stump

Showing results (51-60 of 464) with videos related to

Pageof 47
Sort By:
Gastroenterology|April 18, 2020
Nonalcoholic Fatty Liver Disease in 2020Jacquelyn J Maher, Jörn M Schattenberg
Expert Review of Molecular Diagnostics|August 4, 2021
Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practiceSaleh A Alqahtani, Jörn M Schattenberg
United European Gastroenterology Journal|May 14, 2022
The unmet need of personalized HCC screening-Lessons learned from the Swedish nationwide registriesSimon Johannes Gairing, Jörn M Schattenberg
United European Gastroenterology Journal|May 27, 2020
Liver injury in COVID-19: The current evidenceSaleh A Alqahtani, Jörn M Schattenberg
Redox Biology|December 3, 2014
Regulation of the effects of CYP2E1-induced oxidative stress by JNK signalingJörn M Schattenberg, Mark J Czaja
JHEP Reports : Innovation in Hepatology|July 11, 2026
The Use of FGF21 Analogues in MASH and MASH Cirrhosis - Metabolic Master Regulators or Liver-Specific Mechanisms? <sup>☆</sup>A G Holleboom, J M Schattenberg
Innere Medizin (Heidelberg, Germany)|October 24, 2024
[Acute abdominal pain with surprising etiology-rare complication of a common disease]Katharina Grotemeyer, Roxana Motronea, Jörn M Schattenberg
Deutsches Arzteblatt International|June 11, 2021
In ReplyJörn M Schattenberg, Yvonne Huber, Karel Kostev
Liver International : Official Journal of the International Association for the Study of the Liver|March 19, 2025
Large Language Models in MASLD: The New Era of Generative Artificial Intelligence-Augmented Clinical PracticeNicola Pugliese, Mauro Giuffrè, Jörn M Schattenberg
Expert Opinion on Investigational Drugs|October 19, 2020
The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future successJoost P H Drenth, Jörn M Schattenberg
Pageof 47

Showing results (51-60 of 464) with videos related to

Sort By:
Pageof 47
Gastroenterology|April 18, 2020
Nonalcoholic Fatty Liver Disease in 2020Jacquelyn J Maher, Jörn M Schattenberg
Expert Review of Molecular Diagnostics|August 4, 2021
Nonalcoholic fatty liver disease: use of diagnostic biomarkers and modalities in clinical practiceSaleh A Alqahtani, Jörn M Schattenberg
United European Gastroenterology Journal|May 14, 2022
The unmet need of personalized HCC screening-Lessons learned from the Swedish nationwide registriesSimon Johannes Gairing, Jörn M Schattenberg
United European Gastroenterology Journal|May 27, 2020
Liver injury in COVID-19: The current evidenceSaleh A Alqahtani, Jörn M Schattenberg
Redox Biology|December 3, 2014
Regulation of the effects of CYP2E1-induced oxidative stress by JNK signalingJörn M Schattenberg, Mark J Czaja
JHEP Reports : Innovation in Hepatology|July 11, 2026
The Use of FGF21 Analogues in MASH and MASH Cirrhosis - Metabolic Master Regulators or Liver-Specific Mechanisms? <sup>☆</sup>A G Holleboom, J M Schattenberg
Innere Medizin (Heidelberg, Germany)|October 24, 2024
[Acute abdominal pain with surprising etiology-rare complication of a common disease]Katharina Grotemeyer, Roxana Motronea, Jörn M Schattenberg
Deutsches Arzteblatt International|June 11, 2021
In ReplyJörn M Schattenberg, Yvonne Huber, Karel Kostev
Liver International : Official Journal of the International Association for the Study of the Liver|March 19, 2025
Large Language Models in MASLD: The New Era of Generative Artificial Intelligence-Augmented Clinical PracticeNicola Pugliese, Mauro Giuffrè, Jörn M Schattenberg
Expert Opinion on Investigational Drugs|October 19, 2020
The nonalcoholic steatohepatitis (NASH) drug development graveyard: established hurdles and planning for future successJoost P H Drenth, Jörn M Schattenberg
Pageof 47